Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran Cermin Dunia Kedokteran
Hastarita Lawrenti
Dokter umum
Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Terapi Kanker Payudara Stadium Lanjut HER2 (+) Hastarita Lawrenti
Cermin Dunia Kedokteran Vol 50 No 10 (2023): Kedokteran Umum
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v50i10.915

Abstract

Approximately 15-20% of breast cancers harbor human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification. This subtype of breast cancer is associated with aggressive behavior, high recurrence rates, and worse prognosis. However, with the introduction of HER2-targeted therapy, trastuzumab, the survival rates have greatly improved. In patients with HER2 positive advanced disease, taxane in combination with trastuzumab and pertuzumab is given in the first-line setting. In the second-line setting and beyond, several emerging anti-HER2 therapies are becoming available including trastuzumab deruxtecan, tucatinib, T-DM1, neratinib, lapatinib, pyrotinib, margetuximab.
Terapi Kanker Payudara Stadium Lanjut HER2 (+) Hastarita Lawrenti
Cermin Dunia Kedokteran Vol 50 No 10 (2023): Kedokteran Umum
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v50i10.915

Abstract

Approximately 15-20% of breast cancers harbor human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification. This subtype of breast cancer is associated with aggressive behavior, high recurrence rates, and worse prognosis. However, with the introduction of HER2-targeted therapy, trastuzumab, the survival rates have greatly improved. In patients with HER2 positive advanced disease, taxane in combination with trastuzumab and pertuzumab is given in the first-line setting. In the second-line setting and beyond, several emerging anti-HER2 therapies are becoming available including trastuzumab deruxtecan, tucatinib, T-DM1, neratinib, lapatinib, pyrotinib, margetuximab.
Co-Authors